AI Generated Image
Ophthalmology venture grabs investors’ attention, raises $330 million
statnews.com • • business
Key Points:
- Ollin Biosciences has raised $330 million in a Series B funding round to advance treatments for eye diseases, including diabetic macular edema and wet age-related macular degeneration.
- The startup is preparing to initiate a Phase 3 clinical trial for its treatment targeting these conditions, which affect millions and can cause vision loss.
- The funding round was co-led by TCGX and ARCH Venture Partners and included a mix of established biotech investors, a pension fund, and crossover investors.
- This Series B round is among the largest for a biotech company in the past two years, highlighting strong investor confidence in Ollin's pipeline.
